Search results for abx831313

Lulizumab, Abbexa, abx831313

Lulizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD28, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Lulizumab pegol is under investigation in clinical trial NCT02843659, Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome.